Published in Eur J Clin Pharmacol on November 17, 2005
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol (2014) 2.17
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2010) 1.71
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol (2013) 1.40
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov (2010) 1.33
Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol (2006) 1.18
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol (2013) 1.17
Laboratory assessment of rivaroxaban: a review. Thromb J (2013) 1.16
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol (2014) 1.10
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. Biomed Res Int (2015) 0.95
Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2013) 0.93
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag (2014) 0.91
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care (2013) 0.87
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol (2009) 0.86
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet (2014) 0.86
Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev (2012) 0.86
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag (2015) 0.84
Rivaroxaban and hemostasis in emergency care. Emerg Med Int (2014) 0.84
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol (2013) 0.84
The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag (2015) 0.84
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace (2012) 0.84
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014) 0.83
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis (2013) 0.83
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vasc Health Risk Manag (2012) 0.83
A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics. CPT Pharmacometrics Syst Pharmacol (2015) 0.83
Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol (2008) 0.83
Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel) (2012) 0.82
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82
Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82
Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther (2014) 0.81
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81
Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor. P T (2009) 0.81
Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor. Front Physiol (2014) 0.81
Measurement and reversal of the direct oral anticoagulants. Blood Rev (2016) 0.80
Practical management of new oral anticoagulants after total hip or total knee arthroplasty. Musculoskelet Surg (2013) 0.80
New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T (2011) 0.80
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol (2009) 0.80
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2012) 0.80
Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther (2016) 0.79
Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis (2012) 0.79
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag (2014) 0.79
Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vasc Health Risk Manag (2011) 0.79
Recent advances in the management of venous thromboembolism. Korean J Hematol (2010) 0.78
Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. Br J Clin Pharmacol (2015) 0.78
Medical management of venous thromboembolism: what the interventional radiologist needs to know. Semin Intervent Radiol (2012) 0.78
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag (2008) 0.78
Reversal of target-specific oral anticoagulants. Drug Discov Today (2014) 0.78
Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians. Thrombosis (2013) 0.78
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants (DOACs): A Systematic Review. Chest (2016) 0.78
Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc Health Risk Manag (2014) 0.77
XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thromb J (2014) 0.77
Algorithm for anticoagulation management in geriatric hip fracture patients--Surgeons save Blood. Z Gerontol Geriatr (2014) 0.77
New anticoagulants for the prevention of venous thromboembolism. Drug Des Devel Ther (2010) 0.76
Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag (2013) 0.76
Selecting antithrombotic therapy for patients with atrial fibrillation. Cleve Clin J Med (2015) 0.75
Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies. Br J Clin Pharmacol (2015) 0.75
Development of oral anticoagulants. Br J Clin Pharmacol (2007) 0.75
Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. Cardiovasc Drugs Ther (2016) 0.75
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterol Res Pract (2016) 0.75
New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients (2015) 0.75
Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. Ther Clin Risk Manag (2012) 0.75
Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice? Arrhythm Electrophysiol Rev (2016) 0.75
The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. Indian Heart J (2015) 0.75
New oral anticoagulants. CMAJ (2012) 0.75
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. Clin Drug Investig (2016) 0.75
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. Vasc Health Risk Manag (2008) 0.75
Rivaroxaban in atrial fibrillation. Vasc Health Risk Manag (2012) 0.75
Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. Ther Adv Hematol (2012) 0.75
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. Acad Emerg Med (2015) 0.75
Drug-induced liver injury: Towards early prediction and risk stratification. World J Hepatol (2017) 0.75
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention. P T (2011) 0.75
Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vasc Health Risk Manag (2014) 0.75
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. Ther Clin Risk Manag (2014) 0.75
The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol (2013) 0.75
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clin Appl Thromb Hemost (2016) 0.75
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm (2017) 0.75
Use of rivaroxaban in patients with stroke. Neurol Sci (2017) 0.75
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol (2017) 0.75
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA (2000) 13.68
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther (2005) 2.63
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost (2005) 2.16
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost (2005) 1.60
Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost (1995) 1.25
Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol (1999) 1.10
Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. Xenobiotica (2005) 0.91
Current options in the prevention of thromboembolic disease. Drugs (2004) 0.85
New anticoagulants and their potential impact on the treatment of thromboembolic disease. Curr Hematol Rep (2004) 0.75
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther (2005) 2.63
Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation (2009) 1.76
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2010) 1.71
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol (2008) 1.43
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin (2008) 1.42
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol (2013) 1.40
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol (2007) 1.29
A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet (2006) 1.24
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. J Clin Pharmacol (2006) 1.21
Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol (2006) 1.18
Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol (2010) 1.10
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol (2006) 1.10
First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob Agents Chemother (2008) 1.07
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol (2007) 1.06
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf (2008) 1.03
The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor. J Clin Pharmacol (2013) 1.03
The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther (2013) 1.00
The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr Clin Pharmacol (2006) 0.97
Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol (2014) 0.95
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2013) 0.93
Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine. J Clin Pharmacol (2010) 0.86
Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol (2008) 0.85
Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol (2012) 0.83
Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel) (2012) 0.82
Quantification of vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor in plasma of cancer patients and healthy volunteers - comparison of ELISA and microsphere-based multiplexed immunoassay. Clin Chem Lab Med (2008) 0.81
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thromb Res (2013) 0.79
Pupil reaction: a valid sensitive clinical biomarker for 5-HT compounds. Basic Clin Pharmacol Toxicol (2005) 0.79
Concentration-effect relationships of alcohol in a computerised psychometric test system. Arzneimittelforschung (2005) 0.78
Influences of caffeine, acetazolamide and cognitive stimulation on cerebral blood flow velocities. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.78
Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs). Int J Clin Pharmacol Ther (2014) 0.77
Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment. J Clin Pharmacol (2011) 0.75
Selective 5-HT(1A)-R-agonist repinotan prevents remifentanil-induced ventilatory depression and prolongs antinociception. Anesthesiology (2012) 0.75